Detecting small cell lung cancer using autoantibodies as biomarkers
Official title: Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
Funded at Fred Hutchinson Cancer Center · NIH-10896444 · Data updated 2026-11-12
This study is looking for ways to find small cell lung cancer earlier by checking for certain antibodies in the blood of people, especially heavy smokers, and using imaging tests to spot tumors, which could help catch the cancer sooner and improve treatment outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $613,760 |
| NIH project number | 5R01CA281801-02 |
| Project ID | NIH-10896444 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are heavy smokers or individuals at high risk for developing small cell lung cancer.
✕Less likely to help
Patients who do not smoke or have no other risk factors for small cell lung cancer may not benefit from this research.
What this research studies
This research focuses on improving the early detection of small cell lung cancer (SCLC) by identifying specific autoantibodies present in the blood of patients. The approach involves a two-tiered strategy that combines a blood test to detect these autoantibodies with non-invasive imaging techniques to confirm the presence of tumors. By targeting high-risk individuals, particularly heavy smokers, the research aims to facilitate timely diagnosis and treatment, potentially improving survival rates. The study leverages previously validated cancer-specific neoantigens to enhance the accuracy of detection.
Why it matters
Potential benefit: If successful, this research could significantly increase the early detection rates of small cell lung cancer, leading to better treatment outcomes and improved survival rates.
How similar studies have gone: Previous research has shown promise in using autoantibodies as biomarkers for cancer detection, indicating that this approach may be effective.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Lampe, Paul D. — Fred Hutchinson Cancer Center
- Study coordinator: Lampe, Paul D.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.